Adverse events of special interest after C-CAR088 T cell infusion (N=31)
| Variable, n (%) | Low-dose group (n=4) | Medium-dose group (n=13) | High-dose group (n=14) | Total (n=31) |
| CRS grade | 3 (75.0) | 13 (100) | 13 (92.9) | 29 (93.5) |
| 1 | 3 (75.0) | 7 (53.8) | 8 (57.1) | 18 (58.1) |
| 2 | 0 (0.0) | 4 (30.8) | 4 (28.6) | 8 (25.8) |
| 3 | 0 (0.0) | 2 (15.4) | 1 (7.1) | 3 (9.7) |
| 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Common CRS symptoms (>20%) | ||||
| Fever | 3 (100) | 13 (100) | 13 (100) | 29 (100) |
| Hypoxia | 0 (0.0) | 5 (38.5) | 3 (23.1) | 8 (27.6) |
| Fibrin D dimer Increased | 1 (33.3) | 4 (30.8) | 2 (15.4) | 7 (24.1) |
| tachycardia | 2 (66.7) | 1 (7.7) | 4 (30.8) | 7 (24.1) |
| Hypotension | 0 (0.0) | 3 (23.1) | 3 (23.1) | 6 (20.7) |
| Increased transaminase | 1 (33.3) | 2 (15.4) | 3 (23.1) | 6 (20.7) |
| CRS onset, days (range) | 9 (4–10) | 8 (2–12) | 4 (2–10) | 7 (2–12) |
| CRS duration, days (range) | 6 (4–17) | 4 (2–9) | 5 (3–14) | 5 (2–17) |
| Tocilizumab alone | 0 (0.0) | 2 (15.4) | 1 (7.1) | 3 (9.7) |
| Corticosteroids alone | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Tocilizumab and corticosteroids | 0 (0.0) | 3 (23.1) | 3 (21.4) | 6 (19.4) |
| ICANS | 0 (0.0) | 0 (0.0) | 1 (7.1) | 1 (3.2) |
| Infection | 2 (50.0) | 10 (76.9) | 9 (64.3) | 21 (67.7) |
| ≥Grade 3 cytopenia not improved within 28 days | 3 (75.0) | 4 (30.8) | 9 (64.3) | 16 (51.6) |
CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome.